HEPATOCELLULAR CARCINOMA DRUGS MARKET ANALYSIS

Regional Analysis

Regional Dynamics

Regional segmentation of the global hepatocellular carcinoma drugs market by Coherent Market Insights comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the global hepatocellular carcinoma drugs market over the forecast period, owing to increasing prevalence of the disease and the rising number of clinical trials undertaken by the manufacturers to address the unmet medical needs of the patients. According to the survey by the Health Science Department, University of California, Los Angeles, (UCLA), 2017, hepatocellular carcinoma (HCC) accounts for three quarters of liver cancers in the U.S. with an estimated 40,000 Americans diagnosed with liver cancer in 2017 and more than 28,000 deaths are reported from the disease. Also, in April 2018, Eli Lilly and Company completed Phase 3 research study of Cyramza (ramucirumab) as a single agent in the second-line treatment of people with hepatocellular carcinoma, also known as liver cancer.

Asia Pacific is expected to gain significant traction in the global hepatocellular carcinoma drugs market owing to rising number of research and development activities undertaken by the manufacturers in the region to develop effective therapies. For instance, in February 2017, Daiichi Sankyo, a pharmaceutical company in Japan completed the Phase-3 study of tivantinib indicated for patients with hepatocellular carcinoma treated with other therapies.